[2020 TEIN/KOICA] Summer Workshop for Malaysia ( Session 2)

[2020 TEIN/KOICA] Summer Workshop for Malaysia ( Session 2)

by MS Suh

Life & Natural Systems Engineering & Technology TJKCommunications engineering
🎙 MS Suh 👥 358 📅 August 18, 2020 ⏱ 51 min 👁 45 📄 expert opinion 🧭 2026-08-18
Available in: English (current) Français

Keywords

theranosticsPRRTPSMAFAPneuroendocrine tumors

Summary

This presentation, part of a 2020 TEIN/KOICA summer workshop for Malaysia, focuses on the clinical application of theranostics in nuclear medicine. The speaker, MS Suh, begins by highlighting the growing interest from pharmaceutical companies in radiopharmaceuticals, citing acquisitions like Novartis’s purchase of AAA and Endocyte. The talk then delves into three main areas: neuroendocrine tumors (NETs), prostate cancer, and future approaches like fibroblast activation protein (FAP) targeting. For NETs, the speaker discusses the use of somatostatin analogs for imaging (e.g., Ga-68 DOTATATE PET) and therapy (e.g., Lu-177 DOTATATE, known as Lutathera), including the NETTER-1 trial that led to FDA approval. Ongoing trials like NETTER-2 and COMPETE are mentioned. For prostate cancer, the focus is on PSMA-targeted therapy with Lu-177-PSMA-617, highlighting the VISION trial and the potential of alpha-particle therapy with Ac-225. The presentation also covers the role of FAP in cancer stroma and its potential as a pan-tumor target, with early imaging results. The speaker concludes by discussing challenges like response evaluation and personalized dosimetry, and notes the slower adoption of these therapies in Korea compared to Malaysia.

178 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation provides a comprehensive overview of current theranostic applications, particularly for NETs and prostate cancer. The speaker supports arguments with references to clinical trials (NETTER-1, VISION) and explains mechanisms of action. However, the argumentation is largely descriptive and lacks critical analysis of limitations or alternative viewpoints. The value lies in its educational content for a specialized audience, but it does not present novel data or in-depth evidence synthesis.

Scientific Rigor, Source Quality, Title Accuracy

The presentation is scientifically sound, but it does not explicitly cite sources during the talk. The description provides no links, so the only sources are the clinical trials mentioned by name. The title accurately reflects the content, which is a workshop session on theranostics. The speaker demonstrates expertise, but the lack of formal citations reduces the rigor. The content aligns with current clinical practice and research directions.

151 words

Title / Content Match

The title accurately describes the content: a session in a summer workshop for Malaysia, focusing on clinical applications of theranostics in nuclear medicine.

Quality & Reliability

7/10

The presentation is given by a medical professional (likely a nuclear medicine specialist) and covers established clinical practices and ongoing trials. However, it is a workshop lecture without formal citations or peer-reviewed references, and some statements are generalizations.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • NETTER-1 trial — Mentioned as a phase 3 clinical trial showing efficacy of Lu-177 DOTATATE in NETs
  • VISION trial — Mentioned as an ongoing phase 3 trial for Lu-177-PSMA-617 in mCRPC
  • NETTER-2 trial — Mentioned as an ongoing trial for higher-grade NETs
  • COMPETE trial — Mentioned as a comparison trial of PRRT vs targeted therapy

Concurring Sources

  • NETTER-1 trial publication — Phase 3 trial of Lu-177-DOTATATE in midgut NETs
  • VISION trial publication — Phase 3 trial of Lu-177-PSMA-617 in mCRPC

Contribution & Novelties

The presentation offers a concise update on theranostics, particularly highlighting the shift towards personalized medicine and the potential of FAP as a pan-tumor target. It underscores the importance of clinical trials in expanding indications and the ongoing debate on alpha vs beta emitters.

Pour aller plus loin :

70 words

Radar Profile

The radar profile shows high scores in quantity and technical level, indicating a dense, specialized presentation. Quality and reliability are moderate, reflecting the lack of formal citations and the reliance on expert opinion.

Reliability 6/10